2023
Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation
Sinha C, Meacham L, Bakshi N, Ross D, Krishnamurti L. Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2023, 70: e30276. PMID: 37051746, PMCID: PMC10544372, DOI: 10.1002/pbc.30276.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationRisk of infertilitySickle cell diseaseStem cell transplantationFertility preservationCell transplantationCell diseaseMajor long-term complicationPrimary caregiversIdentical related donorsDisease-free survivalFertility preservation optionsFertility preservation proceduresLong-term complicationsHuman leukocyte antigenConditioning regimenHost diseaseRelated donorsLeukocyte antigenPreservation optionsHCT physiciansSurvival rateAvailable HLAEleven participantsInfertilitySecondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Eapen M, Brazauskas R, Williams D, Walters M, St Martin A, Jacobs B, Antin J, Bona K, Chaudhury S, Coleman-Cowger V, DiFronzo N, Esrick E, Field J, Fitzhugh C, Kanter J, Kapoor N, Kohn D, Krishnamurti L, London W, Pulsipher M, Talib S, Thompson A, Waller E, Wun T, Horowitz M. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal Of Clinical Oncology 2023, 41: 2227-2237. PMID: 36623245, PMCID: PMC10448940, DOI: 10.1200/jco.22.01203.Peer-Reviewed Original ResearchConceptsLow-intensity regimensSickle cell diseaseSecondary neoplasmsRisk factorsCell diseaseLeukemia/myelodysplastic syndromeMixed donor chimerismReduced-intensity regimensFull donor chimerismHematopoietic cell transplantTotal body irradiationLow-dose radiationGray regression modelsMyeloid mutationsPrior inflammationCell transplantMyelodysplastic syndromeTolerance inductionIntense regimensPlausible etiologyHigh riskRegimensSolid tumorsNeoplasmsMyeloid malignancies
2022
Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance
Stenger E, Xiang Y, Wetzel M, Gillespie S, Chellapandian D, Shah R, Arnold S, Bhatia M, Chaudhury S, Eckrich M, Kanter J, Kasow K, Krajewski J, Nickel R, Ngwube A, Olson T, Rangarajan H, Wobma H, Guilcher G, Horan J, Krishnamurti L, Shenoy S, Abraham A. Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation And Cellular Therapy 2022, 29: 47.e1-47.e10. PMID: 36273784, DOI: 10.1016/j.jtct.2022.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansRetrospective StudiesTransplantation, HomologousConceptsHematopoietic cell transplantationSickle cell diseaseOrgan functionMultivariable analysisBrain magnetic resonance imagingCentral nervous system indicationsPost-HCT patientsRelated bone marrowSevere acute GVHDPredictors of dysfunctionLong-term survivalMagnetic resonance imagingSevere clinical phenotypeAcute GVHDChronic graftIntense conditioningHost diseaseMyeloablative conditioningNeurologic eventsOvert strokeRetrospective cohortMedian ageOrgan dysfunctionCardiac dysfunctionCell transplantation
2021
Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematology 2021, 2021: 181-189. PMID: 34889368, PMCID: PMC8791142, DOI: 10.1182/hematology.2021000251.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellClinical Decision-MakingDonor SelectionGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansTransplantation ConditioningConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationAlternative donorsCell diseaseOutcomes of HCTHLA-identical related donorsSymptomatic sickle cell diseaseNew disease-modifying drugsHost disease (GVHD) prophylaxisHLA-identical siblingsAvailable therapeutic optionsDisease-modifying drugsLong-term outcomesCord blood expansionConditioning regimensDisease prophylaxisRelated donorsOrgan damageHematopoietic progenitor cellsTherapeutic optionsExcellent outcomesCareful counselingAutologous transplantationClinical registry
2019
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study
Krishnamurti L, Neuberg D, Sullivan K, Kamani N, Abraham A, Campigotto F, Zhang W, Dahdoul T, De Castro L, Parikh S, Bakshi N, Haight A, Hassell K, Loving R, Rosenthal J, Smith S, Smith W, Spearman M, Stevenson K, Wu C, Wiedl C, Waller E, Walters M. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal Of Hematology 2019, 94: 446-454. PMID: 30637784, PMCID: PMC6542639, DOI: 10.1002/ajh.25401.Peer-Reviewed Original ResearchConceptsSevere sickle cell diseaseBone marrow transplantationEvent-free survivalSickle cell diseaseMarrow transplantationCell diseaseElevated tricuspid regurgitant jet velocityRegular red blood cell transfusionsSevere SCDDonor bone marrow transplantationOne-year overall survivalSecond bone marrow transplantationTricuspid regurgitant jet velocityRed blood cell transfusionProspective multicenter pilot studyDeveloped chronic GVHDHost disease (GVHD) prophylaxisStable donor chimerismAcute chest syndromeSecondary graft failureBlood cell transfusionHealth-related qualityPhysical function domainProspective clinical trialsRegurgitant jet velocity
2016
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy S, Eapen M, Panepinto J, Logan B, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight A, Kasow K, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus H, Levine J, Krishnamurti L, Margolis D, Megason G, Yu L, Pulsipher M, Gersten I, DiFronzo N, Horowitz M, Walters M, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 2016, 128: 2561-2567. PMID: 27625358, PMCID: PMC5123194, DOI: 10.1182/blood-2016-05-715870.Peer-Reviewed Original ResearchConceptsEvent-free survivalIncidence rateAcute chest syndrome episodesPosterior reversible encephalopathy syndromeSevere sickle cell diseaseUnrelated donor marrow transplantationVaso-occlusive pain crisesAllogeneic bone marrow transplantEffective GVHD prophylaxisGVHD-related deathsHost disease (GVHD) prophylaxisShort-course methotrexateReversible encephalopathy syndromeUnrelated donor transplantsPhase 2 trialBone marrow transplantTranscranial Doppler velocitiesSickle cell diseaseAcute GVHDChronic GVHDEFS ratesEncephalopathy syndromeGVHD prophylaxisTransplant indicationConditioning regimen
2008
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildCyclosporineFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLiving DonorsMaleMycophenolic AcidMyeloablative AgonistsSiblingsTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousConceptsHematopoietic stem cell transplantationSickle cell diseaseRIC regimenCell transplantationCell diseaseEfficacy of HSCTHigh-risk sickle cell diseaseReduced-Intensity Hematopoietic Cell TransplantationAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning regimensEquine antithymocyte globulinHost disease (GVHD) prophylaxisTotal lymphoid irradiationAcceptable therapeutic optionHematopoietic cell transplantationGroup of patientsStem cell transplantationAntithymocyte globulinLymphoid irradiationConditioning regimenMycophenolate mofetilConditioning regimensDisease prophylaxisDonor engraftmentTherapeutic options